Kick Back: The 10 biggest stories you might have missed on Stockhead this week
Link copied to
Here’s what you might have missed on Stockhead this week, but everyone else didn’t, and liked the most.
What did it for you? Was it the unnerving image selection?
The surge of New-York listed Beyond Meat and predictions that the plant-based meat market will be worth US$13.3 billion by 2023 has prompted more companies to break into the space.
There were just two ASX small caps in this market — Roots Sustainable Agricultural Technologies (ASX:ROO) and Wide Open Agriculture (ASX:WOA). Now a third has joined the mix — Jatenergy (ASX:JAT). Read about it here.
WA-based Surefire (ASX:SRN) has just punched 29 holes into a potentially high-grade gold target at the Victory Bore project, just north of Spectrum’s (ASX:SPX) high profile Penny West project.
Commission-free trading, which is great, is gaining momentum around the globe.
It’s only a matter of time before it comes Down Under, threatening local brokerages which rely on commission as a source of income.
“But there’s no such thing as a free lunch!” cautions this guy.
iSignthis (ASX:ISX) was on a scorching run in 2019 — from 20c to $1.70 — until the payments company tripped over its laces, untied by a report from watchdog group Ownership Matters (OM) questioning the company’s governance and accounting practices.
This week, the company released a 12-page response to a list of 17 questions posed by the ASX regarding the company’s operations. It certainly gave investors, analysts and market commentators plenty of material to pore over.
Tantalum, the rarely noticed by-product of lithium mining, could be making a comeback.
Analysts at Roskill reckon that tantalum prices could be on their way up, thanks to “lower than expected growth in lithium demand” that has resulted in delays in the commissioning of lithium refineries in China.
The ‘software as a service’ (SAAS) business model has taken off in the computer software sector over the past few years.
Now, the same concept – where companies sell a subscription instead of a perpetual license for a one-off fee — is gaining traction in medtech. Check out the smalls caps set to benefit.
1: The company provides solutions to real-world problems
2: It has to include a point of difference “that can’t be replicated”, and
3: and it has to be globally competitive.
(More here, for those who didn’t appreciate my crappy TLDR.)
With a market cap approaching $260m Elixinol (ASX:EXL) is the biggest ASX-listed cannabis stock ahead of the $170m market cap Cann Group (ASX:CAN).
And as the only member of ‘cannabis corner’ with a respectable revenue and earnings track record, it is a unicorn stock in a sector that is yet to live up to its promises, says Dr Boreham (note: not a real doctor).
In this column, we put the microscope on some tiny, sub $10m market cap companies.
Some of them might be garbage, but it’s at the bottom of the ASX barrel where savvy punters could find the next breakout stock.
Got a few dollars? Let’s go shopping.
For lithium plays and their investors, it’s been dire times lately. But evidence is mounting that for both prices — and accompanying sentiment — an upswing is on the horizon.
That’s it from us. Take care folks, see you next week.